3 results
Not approvedWill not start
Primary objectiveTo assess whether the use of alimemazine improves symptoms of allergic diseases and ADHD, as scored by the parents using standardized questionnaires (Sample Snap IV rating scales)
Approved WMOCompleted
Compare Progression Free Survival (PFS) for brivanib versus placebo in subjects with advanced solid tumors with FGF-2 over-expression and who have obtained stable disease after 12 weeks of treatment with brivanib separately for each tumor.
Approved WMOWill not start
To compare the progression-free survival (PFS) in subjects with pancreatic islet cell tumors treated with sunitinib at a starting dose of 37.5 mg daily (continuous dosing) with those treated with placebo.